GSK gets FDA approval for Nucala to treat hypereosinophilic syndrome

This article was originally published here

Nucala has been approved to treat adult and paediatric patients aged 12 years and older with HES ≥ six months without an identifiable non-haematologic secondary cause. Mepolizumab, the

The post GSK gets FDA approval for Nucala to treat hypereosinophilic syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply